肝癌是全球范围内主要的癌症负担之一。在中国的癌症种类中，原发性肝癌名列第四，并且它也是引发癌症相关死亡的第二大主要因素，这对我国人民的身体健康造成了巨大的压力。因为早期肝癌并未表现出明确的临床症状，70%-80%的病人在被诊断出来之前就已经进入了晚期。作为一种新兴科技，影像组学能够从CT、PET或MRI等医学影像中提取高通量的影像学特征并进行分析，以此构建预测模型，给我们带来了全新的观察视野。该技术已在肝脏良恶性疾病的鉴别、肝癌病理的分级预测以及临床治疗的预后评估等多个领域展现了强大的潜力和优势。研究数据显示，影像组学在准确度、灵敏度和特异度等关键指标上都展现出了卓越的性能，预示着它广阔的发展前景和巨大的应用价值。

[1] 原发性肝癌诊疗指南(2024年版)[J].磁共振成像,2024,15(06):1-18.
[2] Zheng RS,Chen R,Han BF,Wang SM,Li L,Sun KX,Zeng HM,Wei WW,He J:[Cancer incidence and mortality in China,2022].Zhonghua Zhong Liu Za Zhi 2024,46(3):221-231.
[3] Zhou M,Wang H,Zeng X,Yin P,Zhu J,Chen W,Li X,Wang L,Wang L,Liu Y et al:Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017.Lancet 2019,394(10204):1145-1158.
[4] Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A:Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin 2018,68(6):394-424.
[5] Wang J,Kato F,Oyama-Manabe N,Li R,Cui Y,Tha KK,Yamashita H,Kudo K,Shirato H:Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI:A Pilot Radiomics Study.PLoS One 2015,10(11):e0143308.
[6] Aerts HJ,Velazquez ER,Leijenaar RT,Parmar C,Grossmann P,Carvalho S,Bussink J,Monshouwer R,Haibe-Kains B,Rietveld D et al:Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.Nat Commun 2014,5:4006.
[7] Zhou Y,Su GY,Hu H,Ge YQ,Si Y,Shen MP,Xu XQ,Wu FY:Radiomics analysis of dual-energy CT-derived iodine maps for diagnosing metastatic cervical lymph nodes in patients with papillary thyroid cancer.Eur Radiol 2020,30(11):6251-6262.
[8] Lambin P,Rios-Velazquez E,Leijenaar R,Carvalho S,van Stiphout RG,Granton P,Zegers CM,Gillies R,Boellard R,Dekker A et al:Radiomics:extracting more information from medical images using advanced feature analysis.Eur J Cancer 2012,48(4):441-446.
[9] Zhao X,Liang P,Yong L,Jia Y,Gao J:Radiomics Study for Differentiating Focal Hepatic Lesions Based on Unenhanced CT Images.Frontiers in Oncology 2022,12.
[10] Jung DH,Hwang S,Hong SM,Chung YK,Song GW,Lee YJ,Kim KH,Ahn CS,Moon DB,Ha TY et al:Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification.World J Surg 2017,41(5):1347-1357.
[11] Futsukaichi Y,Tajiri K,Kobayashi S,Nagata K,Yasumura S,Takahara T,Minemura M,Yasuda I:Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib:case report and review of the literature.Clin J Gastroenterol 2019,12(2):128-134.
[12] Saboo SS,Krajewski KM,Jagannathan JP,O'Regan KN,Odze R,Ramaiya N,Wolpin BM:Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma.Cancer Imaging 2011,11(1):37-41.
[13] Sagrini E,Iavarone M,Stefanini F,Tovoli F,Vavassori S,Maggioni M,Renzulli M,Salvatore V,Stefanescu H,Colombo M et al:Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma.United European Gastroenterol J 2019,7(1):69-77.
[14] Gera S,Ettel M,Acosta-Gonzalez G,Xu R:Clinical features,histology,and histogenesis of combined hepatocellular-cholangiocarcinoma.World J Hepatol 2017,9(6):300-309.
[15] Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Bray F:Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin 2021,71(3):209-249.
[16] Heimbach JK,Kulik LM,Finn RS,Sirlin CB,Abecassis MM,Roberts LR,Zhu AX,Murad MH,Marrero JA:AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology 2018,67(1):358-380.
[17] Siegel RL,Miller KD,Fuchs HE,Jemal A:Cancer Statistics,2021.CA Cancer J Clin 2021,71(1):7-33.
[18] Ronot M,Fouque O,Esvan M,Lebigot J,Aube C,Vilgrain V:Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm.J Hepatol 2018,68(4):715-723.
[19] 郝敬军,庄伟雄,崔凌,等.小肝细胞癌的不典型CT表现分析[J].罕少疾病杂志,2019,26(01):63-65+2.
[20] Yan-hu X,Zhong-jiang H,Yue-hong H:Application of Enhanced CT-based Radiomics in Differentiating Small Hepatocellular Carcinoma from Hepatic Dysplastic Nodules.2023.
[21] Makarova-Rusher OV,Altekruse SF,McNeel TS,Ulahannan S,Duffy AG,Graubard BI,Greten TF,McGlynn KA:Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.Cancer 2016,122(11):1757-1765.
[22] Abdelsalam ME,Murthy R,Avritscher R,Mahvash A,Wallace MJ,Kaseb AO,Odisio BC:Minimally invasive image-guided therapies for hepatocellular carcinoma.J Hepatocell Carcinoma 2016,3:55-61.
[23] 杜国智,宋彬,杨卫东,等.基于CT的影像组学联合血清甲胎蛋白水平预测肝癌病理分级的价值[J].中国医学装备,2021,18(06):68-71.
[24] Zhang X,El-Serag HB,Thrift AP:Predictors of five-year survival among patients with hepatocellular carcinoma in the United States:an analysis of SEER-Medicare.Cancer Causes Control 2021,32(4):317-325.
[25] Allemani C,Matsuda T,Di Carlo V,Harewood R,Matz M,Niksic M,Bonaventure A,Valkov M,Johnson CJ,Esteve J et al:Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.Lancet 2018,391(10125):1023-1075.
[26] Fujiwara N,Friedman SL,Goossens N,Hoshida Y:Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.J Hepatol 2018,68(3):526-549.
[27] Zhou L,Rui JA,Zhou WX,Wang SB,Chen SG,Qu Q:Edmondson-Steiner grade:A crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio.Pathol Res Pract 2017,213(7):824-830.
[28] Sasaki K,Matsuda M,Ohkura Y,Kawamura Y,Inoue M,Hashimoto M,Ikeda K,Kumada H,Watanabe G:The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size.World J Surg 2015,39(5):1134-1141.
[29] Rebouissou S,Nault JC:Advances in molecular classification and precision oncology in hepatocellular carcinoma.J Hepatol 2020,72(2):215-229.
[30] Pawlik TM,Gleisner AL,Anders RA,Assumpcao L,Maley W,Choti MA:Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy:implications for transplant eligibility.Ann Surg 2007,245(3):435-442.
[31] Pirisi M,Leutner M,Pinato DJ,Avellini C,Carsana L,Toniutto P,Fabris C,Boldorini R:Reliability and Reproducibility of the Edmondson Grading of Hepatocellular Carcinoma Using Paired Core Biopsy and Surgical Resection Specimens.2010.
[32] Wu JS,Feng JL,Zhu RD,Liu SG,Zhao DW,Li N:Histopathological characteristics of needle core biopsy and surgical specimens from patients with solitary hepatocellular carcinoma or intrahepatic cholangiocarcinoma.World J Gastrointest Oncol 2019,11(5):404-415.
[33] Tse JR,Terashima K,Shen L,McWilliams JP,Lu DSK,Raman SS:Safety of percutaneous,image-guided biopsy of hepatocellular carcinoma with and without concurrent ablation.Abdom Radiol(NY) 2022,47(8):2640-2646.
[34] Dahdaleh FS,Naffouje SA,Sherman SK,Kamarajah SK,Salti GI:Tissue Diagnosis Is Associated With Worse Survival in Hepatocellular Carcinoma:A National Cancer Database Analysis.Am Surg 2022, 88(6):1234-1243.
[35] 悦笑斐.基于CT成像预测肝癌微血管侵犯､病理分级和预后的影像组学研究[D].华中科技大学,2023.DOI:10.27157/d.cnki.ghzku.2023.003606.
[36] Meng X-P,Wang Y-C,Ju S,Lu C-Q,Zhong B-Y,Ni C-F,Zhang Q,Yu Q,Xu J,Ji J et al:Radiomics Analysis on Multiphase Contrast-Enhanced CT:A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.Frontiers in Oncology 2020,10.
[37] Yuan C,Wang Z,Gu D,Tian J,Zhao P,Wei J,Yang X,Hao X,Dong D,He N et al:Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. Cancer Imaging 2019,19(1):21.
[38] 马玉萍.基于增强CT的影像组学对肝癌术后肝内早期复发的预测价值[D].东南大学,2021.DOI:10.27014/d.cnki.gdnau.2021.004875.
[39] Zheng BH,Liu LZ,Zhang ZZ,Shi JY,Dong LQ,Tian LY,Ding ZB,Ji Y,Rao SX,Zhou J et al:Radiomics score:a potential prognostic imaging feature for postoperative survival of solitary HCC patients.BMC Cancer 2018,18(1):1148.